Showing results (471-480 of 482) with videos related to
Sort By:
Pageof 49
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.G3 (Bethesda, Md.)|June 23, 2022
Genomics analysis of Drosophila sechellia response to Morinda citrifolia fruit dietZachary Drum, Stephen Lanno, Sara M Gregory, et al.Chemical Biology & Drug Design|January 9, 2008
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activityWilliam C Shakespeare, Yihan Wang, Regine Bohacek, et al.Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agentsChi B Vu, George P Luke, Noriyuki Kawahata, et al.Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.Nature Communications|July 24, 2024
Pannexin-1 channel inhibition alleviates opioid withdrawal in rodents by modulating locus coeruleus to spinal cord circuitryCharlie H T Kwok, Erika K Harding, Nicole E Burma, et al.Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.Journal of Medicinal Chemistry|May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseWei-Sheng Huang, Shuangying Liu, Dong Zou, et al.Journal of Medicinal Chemistry|June 2, 2010
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.Pageof 49